UK Body Recommends Lilly, Amylin Diabetes Drug Bydureon
January 12 2012 - 7:31PM
Dow Jones News
The U.K.'s health-care cost-effectiveness body Friday confirmed
initial guidance recommending Eli Lilly & Co. (LLY) and Amylin
Pharmaceuticals Inc.'s (AMLN) Type 2 diabetes drug Bydureon for use
in the U.K.'s publicly funded National Health Service.
In final guidance, the National Institute for Health and
Clinical Excellence, or NICE, said the injectable medicine, known
generically as exenatide, could be given in combination with
certain other drugs in obese patients with a body mass index above
35, or those for whom insulin injections wouldn't be suitable.
In a statement, NICE said exenatide improves the ability of
patients with Type 2 diabetes to control their blood sugar levels
in a number of ways. These include enhanced glucose-dependent
insulin secretion and reduced glucose-dependent glucagon secretion
in response to eating, which helps stop the liver from
overproducing sugar when it isn't needed.
Carole Longson, NICE's health technology evaluation center
director, said: "2.25 million people in the U.K. are now affected
by Type 2 diabetes, therefore it is important that there are a
range of effective treatment options, such as prolonged-release
exenatide, available to them.
"Type 2 diabetes is a serious, progressive disease; I am sure
all those affected will welcome this positive final draft
recommendation."
-By Sten Stovall, Dow Jones Newswires; +44 207 842 9292;
sten.stovall@dowjones.com
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024